(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
22 June 2023 (22.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/114061 A1

(51) International Patent Classification:
C07D 413/12 (2006.01) *A61P 37/02* (2006.01)
A61P 29/00 (2006.01) *A61K 31/553* (2006.01)

(21) International Application Number:
PCT/US2022/052072

(22) International Filing Date:
07 December 2022 (07.12.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/290,066 16 December 2021 (16.12.2021) US

(71) Applicant: **RIGEL PHARMACEUTICALS, INC.** [US/US]; 1180 Veterans Blvd., South San Francisco, California 94080 (US).

(72) Inventors: **DUAN, Shaoming**; c/o RIGEL PHARMACEUTICALS, INC., 1180 Veterans Boulevard, South San Francisco, California 94080 (US). **SHAW, Simon**; c/o RIGEL PHARMACEUTICALS, INC., 1180 Veterans Boulevard, South San Francisco, California 94080 (US). **WANG, Xin**; c/o RIGEL PHARMACEUTICALS, INC., 1180 Veterans Boulevard, South San Francisco, California 94080 (US).

(74) Agent: **LI, Shenshen** et al.; Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*

WO 2023/114061 A1

(54) Title: CRYSTALLINE FORMS OF A RIPK1 INHIBITOR



(57) Abstract: The present invention provides a crystalline compound of the formula : wherein the crystalline compound is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis, rheumatoid arthritis, and psoriasis.